Based on the results of docking studies, the main ingredients, including isobrucine, vomicine, (s)-stylopine, strychnine, brucine-N-oxide, and brucine, were anticipated to bind to and regulate the function of AKT1, MAPK1, MAPK14, CHRM1, ACHE, or CHRNA4, which could be related targets for the treatment of MG. This evidence concerns the gene CHRNA4 and myasthenia gravis.